Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oscar Kashala

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Advances in Anatomic Pathology|June 29, 2004
PharmacogenomicsJeffrey S Ross, David P Schenkein, Oscar Kashala, et al.
Vaccine|May 16, 2002
Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21Oscar Kashala, Roberto Amador, Maria V Valero, et al.
Journal of Translational Medicine|July 31, 2009
Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanomaAntoni Ribas, John M Kirkwood, Michael B Atkins, et al.
European Journal of Immunology|January 9, 2003
Amino acid dimorphism and parasite immune evasion: cellular immune responses to a promiscuous epitope of Plasmodium falciparum merozoite surface protein 1 displaying dimorphic amino acid polymorphism are highly constrainedClaudia A Daubenberger, Beatrice Nickel, Carlo Ciatto, et al.
Cancer|October 13, 2006
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumorsDavid P Ryan, Leonard J Appleman, Thomas Lynch, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trialPrimo N Lara, Mariana Koczywas, David I Quinn, et al.
Cancer|November 1, 2006
A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumorsDavid P Ryan, Bert H O'Neil, Jeffrey G Supko, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2006
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancerMichael P Fanucchi, Frank V Fossella, Robert Belt, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Advances in Anatomic Pathology|June 29, 2004
PharmacogenomicsJeffrey S Ross, David P Schenkein, Oscar Kashala, et al.
Vaccine|May 16, 2002
Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21Oscar Kashala, Roberto Amador, Maria V Valero, et al.
Journal of Translational Medicine|July 31, 2009
Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanomaAntoni Ribas, John M Kirkwood, Michael B Atkins, et al.
European Journal of Immunology|January 9, 2003
Amino acid dimorphism and parasite immune evasion: cellular immune responses to a promiscuous epitope of Plasmodium falciparum merozoite surface protein 1 displaying dimorphic amino acid polymorphism are highly constrainedClaudia A Daubenberger, Beatrice Nickel, Carlo Ciatto, et al.
Cancer|October 13, 2006
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumorsDavid P Ryan, Leonard J Appleman, Thomas Lynch, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trialPrimo N Lara, Mariana Koczywas, David I Quinn, et al.
Cancer|November 1, 2006
A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumorsDavid P Ryan, Bert H O'Neil, Jeffrey G Supko, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2006
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancerMichael P Fanucchi, Frank V Fossella, Robert Belt, et al.
Pageof 1